Crispr Therapeutics Ag Is A Biotechnology Company Based In Zugswitzerlandwith Operations In Cambridgemassachusettsfounded In 2013The Company Specializes In Crispr Cas9 Gene Editing Technology To Develop Gene Based Medicines For Serious Diseasesincluding Rare Genetic Disorderscancersand Autoimmune Conditions The Company Has Made Significant Advancements In Its Pipelineincluding Ctx001Which Received Fda Approval In December 2023 For Severe Sickle Cell Disease And Transfusion Dependent Beta Thalassemiaother Investigational Therapiessuch As Ctx110Ctx120And Ctx130Target Various Malignanciescrispr Therapeutics Is Also Exploring Preclinical Candidates In Regenerative Medicine And Autoimmune Programswith A Strong Commitment To Research And Developmentthe Company Reported $684 3 Million In R&D Expenses In 2023 And Holds Numerous Patents To Support Its Innovative Work
